

SUB-SAHARAN AFRICA REGIONAL MEETING
JOHANNESBURG, SOUTH AFRICA 2023



### **CONTENTS**

Maps

COVID-19-Related Policies	1
Additional Requirements	1
Meeting Details	2
General Information	3
Special Sessions	3
Sunday, 5 February	4
Monday, 6 February	4
Tuesday, 7 February	8
Wednesday, 8 February	10
Notes	12
At-A-Glance	14



Back

### **COVID-19-RELATED POLICIES**

#### **VACCINATION**

All in-person HVTN Conference attendees (guests, speakers, staff) are required to provide proof of full COVID-19 vaccination upon registering for the meeting.

For the purposes of this guidance, people are considered fully vaccinated for COVID-19\*:

- Two weeks or more after they have received one booster following the initial 2-dose series (Pfizer-BioNTech or Moderna)
- Two weeks or more after they have received a booster following the initial single-dose vaccine (Johnson and Johnson [J&J]/ Janssen)
- Two weeks after receipt of another complete vaccine regimen authorized by the World Health Organization (WHO)
- \* Additional boosters may be recommended for people age 50 and older as well as moderately or severely immunocompromised.

Attendees who cannot or do not wish to comply with the meeting policy are welcome to join virtually.

#### **MASKING**

All attendees are required to wear a paper surgical mask, N95 mask, or KF94 mask at-all-times at all indoor functions except while eating or drinking. Masks must be worn over the nose and the mouth. Attendees who fail to adhere to the masking requirements may not be allowed to participate in the HVTN Conference in person.

#### **DAILY TESTING**

All attendees are required to complete a daily rapid COVID test and the Proof of Negative COVID Test Result Form before joining each day's activities. Tests will be available at the registration desk Sunday – Wednesday. Please complete the test and the form each day in your hotel room, before 10:00 AM and before arriving at the meeting.

### ADDITIONAL REQUIREMENTS

#### **BEFORE THE MEETING**

Do not attend the HVTN sub-Saharan Africa Regional Meeting in person if you are experiencing, or within the 10 days prior to the conference have experienced, symptoms consistent with COVID-19. If you do not feel well, protect yourself and others and stay home. You should not attend if you believe that you may have been exposed to a confirmed or suspected case of COVID-19, or have been diagnosed with COVID-19 within 5 days prior to the meeting. If you have been diagnosed with COVID-19 within two weeks of the conference, please contact HVTN Travel (vtn.travel@hvtn.org) to receive clearance to attend.

Follow travel restrictions and guidance issued by the region you are traveling to and from.

#### **IN-PERSON EXPERIENCE**

To help ensure your personal safety and comfort, the HVTN has asked the hotel to sanitize all facilities at appropriate intervals and to provide readily available cleaning materials on site.

We are committed to clear COVID-19-related health and safety communication during the event. We encourage all conference participants to monitor our conference website for the latest updates.

To minimize the spread of viruses, please follow these steps:

- Wash your hands regularly and thoroughly for at least 20 seconds each time.
- Sanitize hands regularly throughout the day.
- Properly use masks (paper surgical, N95 or KF94) in all meeting spaces at all events.
- Maintain appropriate physical distance from others and comply with all distancing arranged by meeting organizers; do not move furniture or change room arrangements.
- Isolate in your hotel room and alert conference staff if you feel unwell or start experiencing symptoms consistent with possible COVID-19. Conference staff can work with you to determine and implement next steps.
- The HVTN is committed to providing all necessary equipment to assist in following these guidelines (eg, hand sanitizer stations, signage, event reminders)

#### **AFTER THE MEETING**

If you test positive for COVID-19 up to 14 days after your departure from the conference, please contact HVTN Travel immediately at <a href="https://www.vtn.travel@hvtn.org">vtn.travel@hvtn.org</a>.

#### **MEETING DETAILS**

#### **MEETING VENUE**

Sandton Convention Centre 161 Maude Street Sandton, Gauteng, South Africa Sandton Convention Centre is connected to both meeting hotels by a 3rd floor skybridge

Check-Out Time: Before Noon

#### **MEETING HOTELS**

#### **Sandton Towers**

Corner of Maude and Fifth Street Sandton, 2146

Phone: +27-11-7805555

#### **Sandton Sun Hotel**

Corner Alice Lane and Fifth Street Sandton, Gauteng, South Africa

Phone: +27 11 461 9744 | 0861 44 77 44

#### **MEETING REGISTRATION DESK**

The HVTN registration desk is located at the Sandton Convention Centre (3rd floor as you enter SCC from the meeting hotels)

Sunday, 5 February	16:00 – 19:00
Monday, 6 February	07:00 - 17:20
Tuesday, 7 February	07:00 – 17:30
Wednesday, 8 February	07:00 - 17:00

#### NAME BADGES

All registered meeting delegates will be issued a meeting name badge when they check-in. Name badges are required for all meeting delegates. Please be sure to wear your name badge at all times when attending meeting-related functions. If you do not have a name badge, or you have lost yours, please return to the registration desk and another badge will be issued.

#### **SPEAKER CHECK-IN**

All presenting speakers must check in at the meeting registration desk at least 30 minutes prior to their presentation to hand in their presentation slides, unless they have already done so. Jerry Ockfen will be happy to take your presentation slides as well. The AV technician will be available:

AV TECHNICIAN HOURS	
Monday, 6 February	07:00 - 16:05
Tuesday, 7 February	07:00 - 16:15
Wednesday, 8 February	07:00 – 12:30

#### **HVTN RECEPTION**

Please join your colleagues at the HVTN Reception; there will be food and drinks. We look forward to seeing you there!

Sandton Convention Centre		
Ballroom 150		
Monday, 6 February	19:30 – 22:00	

#### PROGRAM-AT-A-GLANCE

For an overview of the meeting program, please refer to the Program-at-a-Glance on pages 14-21. The sessions are color coded to indicate plenary sessions, open sessions, closed sessions, interpretation, live streaming, and catering.

#### **MEALS**

Monday, 6 February	
Arrival Tea	07:00 - 08:00
Morning Tea	10:15 - 10:30
Lunch	12:45 – 13:45
Afternoon Tea	16:05 – 16:20

on the 2nd floor during Tea or Lunch time, please head to the Ballroom Foyer for food, with seating in your meeting room or Ballroom 3

For those attending sessions

Tuesday, 7 February	
Arrival Tea	07:00 - 08:00
Morning Tea	10:00 - 10:15
Lunch	11:30 - 12:30
Afternoon Tea	16:15 – 16:30

For those attending sessions on the 4th floor during Tea or Lunch time, please head to the Committee Foyer for food, with seating in your meeting room.

Wednesday, 8 February	
Arrival Tea	07:00 - 08:30
Morning Tea	10:45-11:00
Lunch	12:30 - 13:30
Afternoon Tea	15:30 - 16:00

Breakfast has been included with your night's stay where you are staying. Please plan to eat breakfast at your hotel beforehand.

#### PLENARY PRESENTATIONS

Ballroom 150

Monday, 6 February		
Plenary 1	08:00 - 10:15	
Plenary 2	10:30 - 12:45	
Plenary 3	13:45 – 16:05	
Tuesday, 7 February		
Plenary 4:	08:00 - 10:00	
Plenary 5:	10:15 - 11:30	
Plenary 6:	12:30 – 14:45	
Plenary 7:	14:45 – 16:15	
Wednesday, 8 February		
Plenary 8:	08:00 – 09:15	
Plenary 9:	09:15 - 10:45	
Plenary 10:	11:00 – 12:30	

Please note, a majority of the plenary presentation slides will be available on the Members website following the conclusion of the meeting.

 $\frac{https://fredhutch.sharepoint.com/sites/HVTN/hvtn-conference/}{SitePages/2023-February-Regional.aspx}$ 

#### **GENERAL INFORMATION**

#### **MEETING EVALUATIONS**

At the conclusion of the conference, registered participants will be asked to complete a brief online evaluation. The link will be sent to the email address you provided at registration. Your feedback is appreciated as it better prepares our Events staff for future conferences.

#### **INTERNET ACCESS**

Please see the backside of your name badge for details.

#### **INTERPRETATION SERVICES**

OnSiteInsight will provide Portuguese interpretation for all plenaries taking place in Ballroom 150. Interpretation headsets can be picked up inside the ballroom.

#### **SPECIAL SESSIONS**

#### **HVTN FOR FIRST TIMERS**

Is this your first time attending a major meeting hosted by the HIV Vaccine Trials Network?

This session helps to ensure attendees understand the HVTN and how it is designed to support site activity. Attendees will also learn how to build capacity for participating in the meeting as for many, this is their first scientific conference.

Ballroom 2	
Monday, 6 February	07:00 - 08:00

(Be sure to have breakfast at your hotel beforehand.)

#### **BREAKING DOWN THE SCIENCE LUNCHEON**

Formerly known as the Layperson's Lunch, the session is open to everyone and allows plenary speakers to present their work in a simpler and more accessible format, followed by time for questions and discussion.

Ballroom 2	
Monday, 6 February	12:45 – 13:45
Tuesday, 7 February	11:30 - 12:30

#### SPECIAL GUEST

#### **CARL DIEFFENBACH, Ph.D.**

This year we are proud to welcome a special guest, Carl Dieffenbach, Ph.D., to the HVTN Sub-Saharan Africa Regional Meeting. Be sure to attend **Plenary 1** on **Monday, 6 February**, where he will kick off the meeting by joining us for a presentation and Q&A.



Carl W. Dieffenbach, Ph.D., serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than \$1 billion and a staff of more than 150 federal employees. Dr. Dieffenbach is responsible for planning, implementing, managing, and evaluating divisional programs in the following areas:

- Basic laboratory research
- Discovery and development of therapies and treatment strategies for HIV infection, related co-infections and comorbidities, and the complications associated with treated HIV disease through basic research and clinical trials
- Discovery and development of vaccines, topical microbicides, and other prevention strategies through basic research and clinical trials

Dr. Dieffenbach played a key role in restructuring the DAIDSsupported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, professional societies, foundations, community advocacy groups, and industry.

#### **POSTER SESSION**

HVTN and CoVPN researchers share posters presented in the last year at other conferences. You may have noticed them in Ballroom 3 already. Please come to meet with the presenters, while enjoying a glass of wine and some appetizers.

Ballroom 3	
Monday, 6 February	17:50-19:30

Posters will be on display in Ballroom 3 all-day Monday, Tuesday, and Wednesday.



#### SUNDAY,

#### **5 FEBRUARY**

#### Open Registration & Rapid Test Pick-Up

16:00 - 19:00

Sandton Convention Centre

(3rd floor as you enter SCC from

the meeting hotels)

#### MONDAY,

#### 6 FEBRUARY

#### Open Registration & Rapid Test Pick-Up

07:00 - 17:20

Sandton Convention Centre

(3rd floor as you enter SCC from the meeting hotels)

BREAKFAST

06:30 - 08:00

06:30 - 08:00 In the hotel where you are staying

**ARRIVAL TEA** 

07:00 - 08:00

07:00 - 08:00

Ballroom Foyer and Committee Foyer

#### SPECIAL SESSION

07:00 - 08:00

#### **HVTN** for First Timers •

07:00 - 08:00

Ballroom 2

Open

Session chair: Stephaun Wallace, PhD

Is this your first time attending a major meeting hosted by the HIV Vaccine Trials Network?

This session helps to ensure attendees understand the HVTN and how it is designed to support site activity. Attendees will also learn how to build capacity for participating in the meeting as for many, this is their first scientific conference.

#### PLENARY 1 0 \*

08:00 - 10:15

## HIV Monoclonal Antibodies & Long Acting Antivirals

08:00 - 10:15 Ballroom 150

Session chairs: Erica Lazarus, MBCHB, DipHIVMan, DCH &

Nono Mkhise, PhD

Perinatal HIV Research Unit &

National Institute of Communicable Diseases

#### Opening Remarks

08:00 – 08:05 Glenda Gray, MBBCh, FCPaed, DSc South African Medical Research Council

#### PLENARY 1 •\*

08:00 - 10:15

 Presentation / Q&A with Special Guest, Carl Dieffenbach, Ph.D.

08:05 - 08:30

Carl Dieffenbach, PhD

National Institutes of Health

 Long-Acting PrEP & mAbs & How to Go to Scale in E & S Africa for Both of Them

08:30 - 08:45

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP, PhD

Desmond Tutu HIV Centre

 Update on Long-Acting PrEP Rollout and Scale-Up in Zimbabwe - What's Happened to Date?

08:45 - 09:00

Mike Chirenje, MD, FRCOG

University of Zimbabwe

 Standard of Care in HIV mAb Studies - How Do We Do Them in the Age of PrEP?

09:00 - 09:15

Glenda Gray, MBBCh, FCPaed, DSc

South African Medical Research Council

 Why We Want mAbs in the Current HIV Prevention Era

09:15 - 09:30

Tian Johnson

African Alliance & Vaccine Advocacy Resource Group

Update on HVTN/HPTN mAb Studies

09:30 - 09:45

 $Huub\ Gelderblom,\ MD,\ PhD,\ MPH\ /\ Will\ Hahn,\ MD$ 

Fred Hutch

 CAPRISA 012 parts B & C - CAP256V2LS + VRC07-523LS

09:45 - 10:00

Sharana Mahomed, MBChB, FC Path, MMed

Centre for the AIDS Programme of Research in South Africa

Questions & Answers/Discussion

10:00 - 10:15

#### MORNING TEA

10:15 - 10:30

10:15 - 10:30

Ballroom Foyer

PLENARY 2 •\*

#### **COVID Vaccine Science in RSA -Real World Evidence**

10:30 - 12:45 Ballroom 150

Session chairs: Simone Richardson, PhD & Carolyn Williamson, PhD National Institute of Communicable Diseases & University of Cape Town

Long COVID and Vaccination

10:30 - 10:45 Shirley Collie, BS Discovery Health

 Statistical Considerations in Assessing Real World Effectiveness of Vaccines

10:45 - 11:00 Tarylee Reddy, PhD, MSc South African Medical Research Council

Health Care Worker Study - A Focus on HIV

11:00 - 11:15 Ntobeko Ntusi, MBChB, PhD, MD University of Cape Town

 Natural History of COVID-19 in **HIV Infected Persons** 

11:15 - 11:30 Waasila Jassat, MBBCh, MMed, FCPHM National Institute of Communicable Diseases

SARS-CoV-2 Viral Evolution

11:30 - 11:45 Alex Sigal, PhD Africa Health Research Institute/University of KwaZulu-Natal

 People Living With HIV Achieve Equivalent But Delayed Antibody Function after SARS-CoV-2 Infection and Vaccination

11:45 - 12:00 Simone Richardson, PhD National Institute of Communicable Diseases

 Nasal & Upper Respiratory Immunology and COVID

12:00 - 12:15 Lyle McKinnon, PhD University of Manitoba

 Immunity to SARS-CoV-2 Infection and Virus Shedding - Implications for COVID Vaccines

12:15 - 12:30 Daniel Schuster, MD **Duke University** 

Questions & Answers/Discussion

12:30 - 12:45

LUNCH

12:45 - 13:45

12:45 - 13:45

Served in Ballroom Foyer & Committee Foyer with seating in your meeting room or Ballroom 3

SPECIAL SESSION

12:45 - 13:45

Breaking Down the Science Luncheon •

12:45 - 13:45 Ballroom 2

Open Session chair: Kagisho Baepanye

Formerly known as the Layperson's Lunch, the session is open to everyone and allows plenary speakers to present their work in a simpler and more accessible format, followed by time for questions and discussion.

**BREAKOUT SESSIONS** 

12:45 - 13:45

AMP ATI (HVTN 805/HPTN 093) **Operations Meeting** 

12:45 - 13:45 Ballroom 4

Closed Session chairs: Carissa Karg & Azwi Takalani

**RAMP Current Mentors Meeting** 

12:45 - 13:45 Committee Room 2 Session chair: Linda Oseso Closed

PLENARY 3 •\*

13:45 - 16:05

COVID-19 Vaccination - CoVPN 3008, 3005 & What Comes Next?

13:45 - 16:05 Ballroom 150 Session chair: Penny Moore, PhD, MSc NICD

Where is COVID Vaccination Going? **Next Generation Vaccines** 

13:45 - 14:05 Kevin Saunders, PhD **Duke University** 

CoVPN 3008 Ubuntu trial update

14:05 - 14:20 Nigel Garrett, MBBS, PhD, MSc Centre for the AIDS Programme of Research in South Africa

CoVPN 3008 – Analysis of COVID-19 Incidence

14:20 - 14:35 Aaron Hudson, PhD Fred Hutch

Sequencing CoVPN 3008

14:35 - 14:45 Tulio deOliveira, MSc, PhD Stellenbosch University

13:45 - 16:05

CoVPN 3008 - T cell Data

14:45 - 15:00 Faatima Laher Omar, PhD Cape Town Immunology Laboratory

Implementation of a New Pseudovirus Neutralization Assay for COVPN 3008

15:00 - 15:15 Tandile Modise, MSc National Institute of Communicable Diseases

CoVPN Data/Correlates Update

15:15 - 15:30 Yunda Huang, PhD Fred Hutch

CoVPN 3005 Sanofi Trial Results

15:30 - 15:45 Stephen Walsh, MD Harvard University

Boosting in Sub-Saharan Africa - Is It Needed?

15:45 - 16:00 Glenda Gray, MBBCh, FCPaed, DSc South African Medical Research Council

Questions & Answers/Discussion

16:00 - 16:05

AFTERNOON TEA

16:05 - 16:20

16:05 - 16:20

Ballroom Foyer and Committee Foyer

**BREAKOUT SESSIONS** 

16:20 - 17:20

Direct Data Entry - Barriers & Best Practices

16:20 - 17:20 Ballroom 4

Session chair: Pallabi Deb Open

Protocol Chair/Co-Chair Interest Session

16:20 - 17:20 Committee Room 2

Open Session chairs: Alison Roxby & Carissa Karg

HVTN is looking for scientists interested in Protocol Chair and co-Chair roles. Come hear about the responsibilities of protocol chairs and bring your questions.

**BREAKOUT SESSION** 

16:20 - 17:20

Evaluating Hormones & Sex as Immunogenicity Predictors in HVTN 602

16:20 - 17:20 Committee Room 5 Session chair: Paul Edlefsen Closed

#### **BREAKOUT SESSION**

16:20 - 17:50

CAB Breakout Session •

16:20 - 17:50 Ballroom 2

Closed Session chair: Kagisho Baepanye

This closed session provides an opportunity for all CAB representatives to come together to discuss topics proposed by members of the group.

**BREAKOUT SESSION** 

17:20 - 17:50

#### Scientific Leadership Development Award Interest Session

17:20 - 17:50 Committee Room 2 Session chair: Alison Roxby Open

The Scientific Leadership Development award supports HVTN efforts to build a new generation of diverse scientists to lead HIV vaccine clinical trials. Come meet the program director and learn about criteria for applications.

#### **BREAKOUT SESSION**

17:20 - 18:20

#### **HVTN 142 Breakout Session**

17:20 - 18:20 Committee Room 5 Closed Session chair: Carrie Sopher

**BREAKOUT SESSION** 

17:50 - 19:20

#### CER Breakout Session •

17:50 - 19:20 Ballroom 2

Closed Session chair: Matshidiso Malefo

This closed session provides an opportunity for all CER staff members to come together to discuss items proposed by members of the group.

SPECIAL SESSION

17:50 - 19:30

#### **HVTN/CoVPN Poster Session**

17:50 - 19:30 Ballroom 3

Session chair: Troy Martin Open

HVTN and CoVPN researchers share posters presented in the last year at other conferences. You may have noticed them in Ballroom 3 already. Please come to meet with the presenters, while enjoying a glass of wine and some appetizers.

#### **BREAKOUT SESSION**

18:20 - 19:30

CoVPN 3008 Study Team

18:20 - 19:30 Committee Room 5

Closed Session chair: Manuel Villaran

**HVTN RECEPTION** 

19:30 - 22:00

19:30 - 22:00 Ballroom 150

Please join your colleagues at the HVTN Reception; there will be food and drinks. We look forward to seeing you there!

## **HVTN/COVPN POSTER SESSION**

### MONDAY, 6 FEBRUARY

17:50 - 19:30

**BALLROOM 3** 

How adopting the people-centred community practice approach contributed to meaningful community engagement and establishing sustainable stakeholder networks during the COVID-19 pandemic

Blossom Makhubalo Aurum Institute (Klerksdorp, South Africa)

High prevalence of asymptomatic Omicron infection and correlation with CD4 count among adults with HIV enrolling in Ubuntu clinical trial in sub-Saharan Africa

Asa Tapley, MD, MSc HVTN Core

Immunogenicity of the Polyvalent DNA Prime-Protein Boost HIV Vaccine (PDPHV): Results from the HVTN 124 Trial

Shan Lu, MD, PhD University of Massachusetts Medical School

First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS and anti-V3 HIV-1 broadly neutralizing antibody in healthy adult volunteers without HIV

Yunda Huang, PhD Fred Hutch

111111

Analytical Treatment Interruption (ATI) Among African Women with Early ART Initiation with or without VRC01 Circulating at HIV Acquisition: Study Design and Early Observations of Viral Rebound and Control

Shelly Karuna, MD, MPH & Phil Andrew, RN Fred Hutch/HVTN & FHi360/HPTN

A descriptive analysis of PrEP uptake in a vaccine study (HVTN 705) in young African women at a site in Cape Town

Katherine Gill, MBBS University of Cape Town

Symptom duration in COVID-19 convalescent patients: regional and clinical associations

Jorge Gallardo, MD HVTN



# **HVTN RECEPTION**

19:30 - 22:00

**BALLROOM 150** 

#### TUESDAY,

#### 7 FEBRUARY

#### Open Registration & Rapid Test Pick-Up

07:00 - 17:30 Sa

Sandton Convention Centre (3rd floor as you enter SCC from the meeting hotels)

BREAKFAST

06:30 - 08:00

06:30 - 08:00

In the hotel where you are staying

**ARRIVAL TEA** 

07:00 - 08:00

07:00 - 08:00

Ballroom Foyer and Committee Foyer

#### **BREAKOUT SESSIONS**

07:00 - 08:00

## Research and Mentoring Program (RAMP) - International

07:00 - 08:00 Closed Committee Room 2 Session chair: Linda Oseso

PLENARY 4 •\*

08:00-10:00

#### **HVTN Ex Med Program**

08:00 - 10:00 Ballroom 150

Session chair: Margaret McCluskey, RN, MPH, CCRC

U.S. Agency for International Development

 Ex Med Program Overview - CD4bs Mimics, Long-HCDR3 Approaches, and Peptide Immunogens

08:00 - 08:20

Troy Martin, MD, MPH

Fred Hutch

 An Early Look at the Epitope Knock Out and Neutralization Data. Immunogens Designed that are Testing Endpoints, Germline, Intermediate Step Abs

08:20 - 08:40

David Montefiori, PhD

**Duke University** 

 Interrogating the B cell Receptors - A Rapid Assessment for Iteration

08:40 - 09:00

Rachael Parks, PhD & Ollivier Hyrien, PhD

Fred Hutch & Fred Hutch

#### PLENARY 4 •\*

08:00-10:00

#### GC Dynamics: Long-Primed Germinal Centers With Enduring Affinity Maturation & Clonal Migration

09:00 - 09:20

Harry Sutton, PhD

La Jolla Institute of Immunology

 Mutation-Guided Vaccine Design: A Strategy for Boosting of Primed Lineages

09:20 - 09:40

Kevin Wiehe, PhD

**Duke University** 

Questions & Answers/Discussion

09:40 - 10:00

**MORNING TEA** 

10:00 - 10:15

10:00 - 10:15

Ballroom Foyer and Committee Foyer

PLENARY 5 •\*

10:15-11:30

## **TB Vaccines and New Experimental Medicine Approaches**

10:15 - 11: 30 Ballroom 150

Session chairs: Mark Hatherill, MBChB, DCH, MRCP, FCPaed, MMed

& One Dintwe, PhD University of Cape Town

& Cape Town HVTN Immunity Lab

• Why Do We Need a TB Vaccine? Is It Possible?

10:15 - 10: 30

Willem Hanekom, MBchB, PCPaed

African Health Research Institute

BCG Revaccination Correlates Normalization and Update

10:30 - 10:45

Andrew Fiore-Gartland, PhD

Fred Hutch

 Preclinical Testing of the Afrigen TB mRNA Immunogen

10:45 - 11:00

Munyaradzi Musvosi, PhD

University of Cape Town

 Vaccinating With IM vs. Inhaled ID93 Vaccine -What Does the Lung Immunology Look Like?

11:00 - 11:15

Michele Tomasicchio, PhD

University of Cape Town

Panel Discussion

11:15 - 11:30

KEY Plenary

Open Session

Closed Session

Meals and Breaks

Live Streaming

🖈 Interpretation

LUNCH

11:30 - 12:30

11:30 - 12:30

**SPECIAL SESSION** 

11:30 - 12:30

Breaking Down the Science Luncheon •

11:30 - 12:30 Ba

Ballroom 2

Open Session ch

**BREAKOUT SESSIONS** 

Session chair: Kagisho Baepanye

11:30 - 12:30

All Lab Center Lunch Gathering

11:30 - 12:30

Ballroom 4

Open

Session chair: Erica Andersen-Nissen

**Efficacy Trials Working Group** 

11:30 - 12:30

Committee Room 4

Open

Session chairs: Holly Janes &

Susan Buchbinder

PLENARY 6 •\*

12:30-14:45

#### **HVTN Data**

12:30-14:45 Ballroom 150

Session chairs: Nigel Garrett, MBBS, MRCP, MSc, PhD

& Georgia Tomaras, PhD

CAPRISA (eThekwini) & Duke University

HVTN 702 & 705 Correlates

12:30 - 12:45

Georgia Tomaras, PhD

**Duke University** 

 A New Analysis Pipeline to Evaluate Cellular Responses in Imbokodo (HVTN 705/HPX2008) and Future Studies

12:45 - 13:00

Erica Andersen-Nissen, PhD

Cape Town Immunology Laboratory

HVTN 706/HPX3002/Mosaico Results

13:00 - 13:15

Susan Buchbinder, MD,

Bridge HIV/San Francisco Department of Public Health

HVTN 108 P5 DNA/Protein Trial Results

13:15 - 13:30

One Dintwe, PhD

Cape Town Immunology Laboratory

Evaluation of Abs to Circulating Strains in Southern Africa - What Do We Need for Evaluation of Effective Vaccines and mAbs Trials?

13:30 – 13:45 Guido Ferrari, MD Duke University PLENARY 6 • \*

12:30-14:45

AMP - Learning from mAb PK Assays to Support Future Trials

13:45 – 14:00 Kelly Seaton, PhD Duke University

 Comparing the Selective Forces That Act on Lineages from the Placebo and Treatment Arms of AMP

14:00 – 14:15 Ansie Yssel, PhD University of Cape Town

HVTN 703: Investigation of VRC01 Escape

14:15 – 14:30 Lyle Curry, PhD University of Cape Town

Questions & Answers/Discussion

14:30 - 14:45

PLENARY 7 •\*

14:45-16:15

## Triple Monoclonal Ab Efficacy Trial - What Does It Look Like?

14:45-16:15 Ballroom 150

Session chair: Nyaradzo Mgodi, MBChB, MMed University of Zimbabwe

 Three Statistical Designs for Assessing Prevention Efficacy

14:45 – 15:10 Holly Janes, PhD Fred Hutch

 Situational Framing of Three Trial Designs in Sub-Saharan Africa

15:10 - 15:25

Linda-Gail Bekker, MBChB, DTMH, DCH, FCP, PhD Desmond Tutu Health Foundation

 Three Statistical Designs for Neutralization Surrogate Endpoints

15:25 – 15:50 Peter Gilbert, PhD Fred Hutch

Panel Discussion

15:50 – 16:15 Guido Ferrari, MD Duke University

Paul Ruff, University of Witswatersrand, Kennedy Otwombe, Perinatal HIV Research Unit, Nyaradzo Mgodi, University of Zimbabwe, Tian Johnson, African Alliance & Vaccine Advocacy Resource Group, Yunda Huang, Fred Hutch/ SCHARP, Sharana Mahomed, CAPRISA **AFTERNOON TEA** 

16:15 - 16:30

16:15 - 16:30

Ballroom Foyer and Committee Foyer

**BREAKOUT SESSION** 

16:30 - 17:30

## Part 1: Considerations for Triple HIV bnAb Combination AMP Study

16:30 – 17:30 Committee Room 5

Closed Session chair: Huub Gelderblom

**BREAKOUT SESSIONS** 

16:30 - 18:00

#### General Community Session •

16:30 - 18:00 Ballroom 2

Open Session chair: Kagisho Baepanye

This session provides an opportunity for all CAB representatives, Community Advocates, and Community Educators/Recruiters/Liaisons/Outreach Staff to come together to discuss items proposed by members of the group

#### Cross-Protocol Safety Refresher Training

16:30 - 18:00 Ballroom 4

Open Session chair: Simone Hendricks

#### **BREAKOUT SESSION**

18:00 - 19:00

#### **Abstract Writing Workshop**

18:00 - 19:00 Ballroom 4

Open Session chair: Alison Roxby

#### **BREAKOUT SESSION**

18:00 - 19:00

## Part 2: Considerations for Triple HIV bnAb Combination AMP Study

18:00 - 19:00

Committee Room 5

Closed Session chair: Huub Gelderblom

## HVTN 705/HPX 2008 (Imbokodo) Post Study Testing •

18:00 - 19:00

Ballroom 2

Closed

Session chair: Carrie Sopher

### Dinner on your own tonight

There are plenty of restaurants surrounding the Sandton Convention Centre, our host hotels, and the shopping mall. Enjoy!

#### WEDNESDAY,

#### 8 FEBRUARY

#### Open Registration & Rapid Test Pick-Up

07:00 - 17:00

Sandton Convention Centre

(3rd floor as you enter SCC from

the meeting hotels)

**BREAKFAST** 

06:30 - 08:00

06:30 - 08:00

In the hotel where you are staying

**ARRIVAL TEA** 

07:00 - 08:00

07:00 - 08:00

Ballroom Foyer and Committee Foyer

#### **BREAKOUT SESSION**

07:00 - 08:00

#### HVTN 311 Meet & Greet

07:00 – 08:00 Committee Room 2

Closed Session chair: Briana Furch

PLENARY 8 •\*

08:00-09:15

Accredited for CPD Points for RSA Medical Doctors

## **Prevention Evolution - Updating Our Approaches to HIV Prevention in Vaccine Trials**

08:00-09:15 Ballroom 150

Session chair: Fatima Laher, MBBCh, DipHIVMan &

Alison Roxby, MD, MSc

Perinatal HIV Research Unit & Fred Hutch

#### The Sex Positive Approach to Consultation

08:00 - 08:15

Michele Andrasik, PhD

Fred Hutch

#### Implementation of New Prevention Methods in Africa - Long Acting Injectables, Vaginal Ring

08:15 - 08:30

Lynda Stranix-Chibanda, MBChB, MMed

University of Zimbabwe

#### Changing the Low Risk Criteria

08:30 - 08:45

Stephaun Wallace, PhD, MS

Fred Hutch

#### Panel Discussion

08:45 - 09:15

Millicent Atujuna, PhD

Desmond Tutu HIV Foundation

Mbalenhle Sibiya, Counselor, Perinatal HIV Research Unit, Blossom Makhubalo, Community Engagement Manager, Aurum Institute - Klerksdorp, Sibusiso Mngadi, HVTN Global CAB co-Chair, CAPRISA eThekwini CRS, Angy Peter, Community Advocate Groote Schuur CRS 09:15-10:45

#### Vaccine Manufacturing - Bringing to Scale in **South Africa**

09:15-10:45 Ballroom 150 Session chair: Devin Sok, PhD

International AIDS Vaccine Initiative

Making Lipid Nanoparticles in Africa

09:15 - 09:35 Patrick Arbuthnot, MBBCh, PhD University of Witswatersrand

 mRNA Hub: The Hurdles to Fast Tracking mRNA Vaccine Production in Africa

09:35 - 09:55 Petro Terblanche, Managing Director Afrigen Biologics & Vaccines

 Bringing Vaccines to Scale: Transfer of RNA Technology and Pitfalls with Vaccine Production in RSA

09:55 - 10:15 Morena Makhoana, CEO The Biovac Institute

 Transfer of Ad26 Technology for COVID Vaccine Production in RSA

10:15 - 10:35 Stavros Nicolaou, PhD Aspen Pharmacare

Questions & Answers/Discussion

10:35 - 10:45

MORNING TEA

10:45 - 11:00

10:45 - 11:00

Ballroom Foyer and Committee Foyer

PLENARY 10 •\*

11:00-12:30

#### **Pediatric Vaccine Program & Closing Remarks**

11:00-12:30 Ballroom 150

Session chair: Glenda Gray, MBBCh, FCPaed, DSc South African Medical Research Council

Pediatric HIV Vaccine & mAb Strategy

11:00 - 11:15 Troy Martin, MD, MPH / Holly Janes, PhD Fred Hutch

Update on HVTN 135 - BAMA, Neut, ADCC

11:15 - 11:30

Avy Violari, MD, FCPAED & Nono Mkhize, PhD Perinatal HIV Research Unit & National Institute of Communicable Diseases

#### PLENARY 10 • \*

11:00-12:30

#### Adjuvants in the Newborn and Innate Responses in HVTN 135

11:30 - 11:45 Ofer Levy, MD, PhD Harvard University

 Towards a Paediatric mAb Programme to Eliminate Breastmilk Transmission of HIV

11:45 - 12:00 Ameena Goga, MBChB, FC(Paeds), PhD WHO/SAMRC

Questions & Answers/Discussion

12:00 - 12:15

 Closing remarks with Larry Corey & Glenda Gray 12:15 - 12:30

#### LUNCH

12:30 - 13:30

12:30 - 13:30 Served in Ballroom Foyer & Committee Foyer with seating in your meeting room or Ballroom 3

#### **BREAKOUT SESSION**

12:30 - 13:30

#### HVTN 805/HPTN 093 AMP ATI Assay Planning

12:30 - 13:30Committee Room 2 Closed Session chair: Shelly Karuna

#### **BREAKOUT SESSION**

12:30 - 14:00

#### **HVTN 305: Q&A Training Session**

12:30 - 14:00 Committee Room 4 Open Session chair: Briana Furch

#### **BREAKOUT SESSION**

13:30 - 14:30

#### CoVPN 3008 Writing Team

13:30 - 14:30 Boardroom 1/2/3 Closed Session chair: Nicole Na

#### **BREAKOUT SESSION**

13:30 - 16:00

#### Breastmilk Transmission & mAb PMTCT

13:30 - 16:00 Committee Room 5 Closed Session chair: Troy Martin

#### **BREAKOUT SESSION**

14:00 - 16:00

Research & Mentoring Program (RAMP) -Current & Prospective Mentor Workshop

14:00 - 16:00 Committee Room 2 Session chair: Linda Oseso Open

#### **AFTERNOON TEA**

15:30 - 16:00

15:30 - 16:00

Ballroom Foyer and Committee Foyer

# HVTN SCIENTIFIC LEADERSHIP DEVELOPMENT PROGRAM

Our mission is to build the next new generation of diverse scientists to lead HIV vaccine clinical trials around the world.

We congratulate our 2023 awardees, who will receive support for one year to complete an HVTN mentored research project.

Applications for next year's program will open in July 2023 and more information can be found at <a href="https://www.hvtn.org/scientific-programs/scientific-leadership-development.html">https://www.hvtn.org/scientific-programs/scientific-leadership-development.html</a> or by corresponding with Alison Roxby, MD at <a href="mailto:aroxby2@fredhutch.org">aroxby2@fredhutch.org</a>.

#### 2023 Awardees

Mitch Matoga, MBBS, MSc UNC Project Lilongwe Lilongwe, Malawi

Mentor: Mina Hosseinipour

Tariro Chawana, MBChB, MSc, DPhil University of Zimbabwe Clinical Trials Research Centre Harare, Zimbabwe

Mentor: Z. Mike Chirenje & Lynda Stranix-Chibanda

Vimla Naicker, MBChB South African Medical Research Council Durban, South Africa

Mentor: Ameena Goga

Cassie Grimsley Ackerley, MD The Hope Clinic of the Emory Vaccine Center, Atlanta, USA

Mentor: Srilatha Edupuganti

Alfredo Jose Mena Lora, MD University of Illinois Chicago, Chicago, USA

Mentor: Richard Novak











## SUNDAY, 5 FEBRUARY

	***************************************				
TIME	BALLROOM 150	BALLROOM 2	BALLROOM 3	BALLROOM 4	BOARDROOM 1/2/3
6:30					
7:00					
7:30					
8:00					
8:30					
9:00					
9:30					
10:00					
10:30					
11:00					
11:30					
12:00					
12:30					
13:00					
13:30					
14:00					
14:30					
15:00					
15:30					
16:00					
16:30					
17:00					
17:30					
18:00					
18:30					
19:00					
19:30					
17:00 17:30 18:00 18:30 19:00 19:30 20:00 20:30					
20:30					
21:00					
21:30					

KEY

BALLROOM/ **SANDTON** COMMITTEE COMMITTEE COMMITTEE CONVENTION TIME COMMITTEE ROOM 2 ROOM 4 ROOM 5 CENTRE (3RD FLOOR) **FOYERS** 6:30 7:00 7:30 8:00 8:30 9:00 9:30 10:00 10:30 11:00 11:30 12:00 12:30 13:00 13:30 14:00 14:30 15:00 15:30 16:00 16:30 17:00 Open Registration & Rapid Test Pick-Up 17:30 (16:00 - 19:00) 18:00 18:30 19:00 19:30


20:00

20:30

21:00

21:30

## MONDAY, 6 FEBRUARY



8:30 9:00 9:30 10:00 10:30 11:00 11:30 **Open Registration** 12:00 & Rapid Test Pick-Up (7:00 - 17:20) 12:30 13:00 13:30 14:00 14:30 15:00

COMMITTEE COMMITTEE ROOM 2 ROOM 4

Plenary

Open Session

**KEY** 

COMMITTEE ROOM 5

**Closed Session** 

BALLROOM/ COMMITTEE **FOYERS** 

Meals and Breaks

**SANDTON** CONVENTION CENTRE (3RD FLOOR)

Interpretation

TIME

6:30

7:00

7:30

8:00

15:30

16:00

16:30

17:00

17:30

18:00

18:30

19:00

19:30

20:00

20:30

21:00

21:30

Live Streaming

**Arrival Tea** (7:00 - 8:00)

Tea (10:15 - 10:30)

Lunch (12:45 - 13:45)

Tea (16:05 - 16:20)

Evaluating Hormones & Sex As Immunogenicity Predictors in HVTN 602 (16:20 - 17:20)

> HVTN 142 Breakout Session (17:20 - 18:20)

CoVPN 3008 Study Team (18:20 - 19:30)

Protocol Chair/Co-Chair Interest Session (16:20 - 17:20)


RAMP Current Mentors Meeting

(12:45 - 13:45)

Scientific Leadership Development Award Interest (17:20 - 17:50)

## TUESDAY, 7 FEBRUARY

					00455555
TIME	BALLROOM 150	BALLROOM 2	BALLROOM 3	BALLROOM 4	BOARDROOM 1/2/3
6:30			HVTN/CoVPN		
7:00			Posters on Dislpay		
7:30					
8:00	• *				
8:30	Plenary 4: HVTN Ex Med Program				
9:00	(8:00 - 10:00)				
9:30					
10:00	<b>*</b>				
10:30	Plenary 5: TB Vaccines and New Experimental Medicine Approaches				
11:00	(10:15 - 11:30)				
11:30		Breaking Down the Science Luncheon		All Lab Center Lunch Gathering	
12:00		(11:30 - 12:30)		(11:30 - 12:30)	
12:30	• *				
13:00	Plenary 6: HVTN Data				
13:30	(12:30 - 14:45)				
14:00					
14:30	• *				
15:00	Plenary 7: Triple Monoclonal Ab Efficacy Trial -				
15:30	What Does It Look Like? (14:45 - 16:15)				
16:00					
16:30		Conord Community		Cuara Dual and I	
17:00 17:30		General Community Session (16:30 - 18:00)		Cross Protocol Safety Refresher Training	
17:30				(16:30 - 18:00)	
18:00		HVTN 705/HPX2008 (Imbokodo) Post Study		Abstract Writing Workshop	
18:30		Testing (18:00 - 19:00)		(18:00 - 19:00)	
18:00 18:30 19:00 19:30					
19:30					
20:00					
20:30					
21:00					
21:30					



**Closed Session** 

Meals and Breaks

Live Streaming

Interpretation

**KEY** 

Plenary

Open Session

21:00

21:30

## wednesday, 8 FEBRUARY

TIME	BALLROOM 150	BALLROOM 2	BALLROOM 3	BALLROOM 4	BOARDROOM 1/2/3
6:30			HVTN/CoVPN		
7:00			Posters on Dislpay		
7:30					
8:00	Plenary 8: Prevention Evolution -				
8:30	Updating Our Approaches to HIV  Prevention in Vaccine Trials				
9:00	(8:00 - 9:15)				
9:30	* Plenary 9: Vaccine Manufacturing -				
10:00	Bringing to Scale in South Africa				
10:30	(9:15 - 10:45)				
11:00	○ ★ Plenary 10: Pediatric Vaccine Program				
11:30	& Closing Remarks				
12:00	(11:00 - 12:30)				
12:30					
13:00					
13:30					CoVPN 3008 Writing Team
14:00					(13:30 - 14:30)
14:30					
15:00					
15:30					
16:00					
16:30					
17:00 17:30 18:00 18:30 19:00 19:30					
17:30					
18:00					
18:30					
19:00					
19:30					
20:00					
20:30					
21:00					
21:30					

**Closed Session** 

Meals and Breaks


Live Streaming

Interpretation

**KEY** 

Plenary

Open Session



## **Skybridges and HVTN Registration located on 3rd floor**

